SDS-Page
COVID 19 Spike protein (D614G variant) Coronavirus Recombinant Protein | COVID-19 recombinant protein
Recombinant SARS-CoV-2 Spike protein, D614G variant
Applications
Western Blot
Purity
Affinity chromatography. >90% as estimated by SDS-PAGE stained with Instant Blue Stain (Expedeon).
Synonyms
COVID 19 Spike protein (D614G variant) Coronavirus; Recombinant SARS-CoV-2 Spike protein; D614G variant; 2019 Novel Coronavirus; Coronavirus; CoV; COVID-19 virus; HCoV-2; Human Coronavirus 2019; SARS2; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Spike protein (D614G variant); COVID-19 recombinant protein
Host
HEK293 Cells
Purity/Purification
Affinity chromatography. >90% as estimated by SDS-PAGE stained with Instant Blue Stain (Expedeon).
Form/Format
Liquid. PBS 20% Glycerol
Sequence Positions
16-1213aa
Sequence
VNLTTRTQLP PAYTNSFTRG VYYPDKVFRS SVLHSTQDLF LPFFSNVTWF HAIHVSGTNGTKRFDNPVLP FNDGVYFAST EKSNIIRGWI FGTTLDSKTQ SLLIVNNATN VVIKVCEFQFCNDPFLGVYY HKNNKSWMES EFRVYSSANN CTFEYVSQPF LMDLEGKQGN FKNLREFVFKNIDGYFKIYS KHTPINLVRD LPQGFSALEP LVDLPIGINI TRFQTLLALH RSYLTPGDSSSGWTAGAAAY YVGYLQPRTF LLKYNENGTI TDAVDCALDP LSETKCTLKS FTVEKGIYQTSNFRVQPTES IVRFPNITNL CPFGEVFNAT RFASVYAWNR KRISNCVADY SVLYNSASFSTFKCYGVSPT KLNDLCFTNV YADSFVIRGD EVRQIAPGQT GKIADYNYKL PDDFTGCVIAWNSNNLDSKV GGNYNYLYRL FRKSNLKPFE RDISTEIYQA GSTPCNGVEG FNCYFPLQSYGFQPTNGVGY QPYRVVVLSF ELLHAPATVC GPKKSTNLVK NKCVNFNFNG LTGTGVLTESNKKFLPFQQF GRDIADTTDA VRDPQTLEIL DITPCSFGGV SVITPGTNTS NQVAVLYQGVNCTEVPVAIH ADQLTPTWRV YSTGSNVFQT RAGCLIGAEH VNNSYECDIP IGAGICASYQTQTNSPGGAS VASQSIIAYT MSLGAENSVA YSNNSIAIPT NFTISVTTEI LPVSMTKTSVDCTMYICGDS TECSNLLLQY GSFCTQLNRA LTGIAVEQDK NTQEVFAQVK QIYKTPPIKDFGGFNFSQIL PDPSKPSKRS FIEDLLFNKV TLADAGFIKQ YGDCLGDIAA RDLICAQKFNGLTVLPPLLT DEMIAQYTSA LLAGTITSGW TFGAGAALQI PFAMQMAYRF NGIGVTQNVLYENQKLIANQ FNSAIGKIQD SLSSTASALG KLQDVVNQNA QALNTLVKQL SSNFGAISSVLNDILSRLDP PEAEVQIDRL ITGRLQSLQT YVTQQLIRAA EIRASANLAA TKMSECVLGQSKRVDFCGKG YHLMSFPQSA PHGVVFLHVT YVPAQEKNFT TAPAICHDGK AHFPREGVFVSNGTHWFVTQ RNFYEPQIIT TDNTFVSGNC DVVIGIVNNT VYDPLQPELD SFKEELDKYFKNHTSPDVDL GDISGINASV VNIQKEIDRL NEVAKNLNES LIDLQELGKY EQYIKWPSGGSGYIPEAPRD GQAYVRKDGE WVLLSTFLGS HHHHHHHH
Applicable Applications for COVID-19 recombinant protein
Western Blot (WB), Immunoassay (IA), Functional Studies
Source
Human
Species
Severe Acute Respiratory Syndrome Coronavirus 2
Tag
8xHis at the C-terminus
Endotoxin
Less than 0.1ng/ug (1 IEU/ug), as measured by LAL method.
Dry Ice Shipment
Extra charge fee may add to your shipping cost as dry ice is required to ship this product.
Preparation and Storage
Store at -20 degree or -70 degree C for at least 12 months
Shipping: Dry ice or frozen gel packs
Shipping: Dry ice or frozen gel packs
SDS-Page
SDS-Page
Related Product Information for COVID-19 recombinant protein
Recombinant SARS-CoV-2 Spike protein, D614G variant. Full-length soluble with foldon trimerization motif, mutated Furin recognition site and 2 stabilising mutations (K986P and V987P), based on/modified from Amanat et al, 2020.
The first reports of a typical pneumonia in China were announced at the very end of 2019,in the city of Wuhan, Hubei province. Its cause was identified in January 2020 as a novel betaCoV (1), named SARS-CoV-2, which started spreading very quickly causing a globalpandemic COVID-19.Spike protein attaches the virion to the cell membrane by interacting with host receptor,initiating the infection. Binding to human ACE2 receptor and internalization of the virus into the endosomes of the host cell induces conformational changes in the Spike glycoprotein (2,3). The protein forms a trimer in vivo mediating receptor binding and membrane fusion (4). It has been demonstrated by Florian Krammer's group that certain mutations and the inclusion of trimerization motif can stabilize recombinant Spike protein (5, 6).The original Wuhan strain of the virus has become quickly replaced by its more transmissible variant, mainly determined by a single amino acid point mutation D614G (7).
The first reports of a typical pneumonia in China were announced at the very end of 2019,in the city of Wuhan, Hubei province. Its cause was identified in January 2020 as a novel betaCoV (1), named SARS-CoV-2, which started spreading very quickly causing a globalpandemic COVID-19.Spike protein attaches the virion to the cell membrane by interacting with host receptor,initiating the infection. Binding to human ACE2 receptor and internalization of the virus into the endosomes of the host cell induces conformational changes in the Spike glycoprotein (2,3). The protein forms a trimer in vivo mediating receptor binding and membrane fusion (4). It has been demonstrated by Florian Krammer's group that certain mutations and the inclusion of trimerization motif can stabilize recombinant Spike protein (5, 6).The original Wuhan strain of the virus has become quickly replaced by its more transmissible variant, mainly determined by a single amino acid point mutation D614G (7).
References
1. Zhu N., Zhang D., Wang W., et al. China Novel Coronavirus Investigating and Research Team. Anovel coronavirus from patients with pneumonia in China, 2019. N Engl J Med., 2020;382:727-733.
2. Hoffmann M., Kleine-Weber H., Schroeder S., et al. SARS-CoV-2 Cell Entry Depends on ACE2 andTMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020;181(2):271-280.
3. Wrapp D., Wang N., Corbett KS., et al. Cryo-EM structure of the 2019-nCoV spike in the prefusionconformation. Science, 2020;367(6483):1260-1263.
4. Yin HS., Wen X., Paterson RG., Lamb RA., Jardetzky TS. Structure of the para influenza virus 5 Fprotein in its metastable, prefusion conformation. Nature, 2006;439(7072):38-44.
5. Amanat, F., Stadlbauer, D., Strohmeier, S., et al. A serological assay to detect SARS-CoV-2seroconversion in humans. Nat Med., 2020;26:1033-1036.
6. Stadlbauer, D., Amanat, F., Chromikova, V., et al. SARS?CoV?2 sero conversion in humans: A detailed protocol for a serological assay, antigen production, and test setup. Current Protocols in Microbiology, 2020;57, e100.
7. Korber, B., W. Fischer, Gnanakaran, S., et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell, 2020;182:1-16.
2. Hoffmann M., Kleine-Weber H., Schroeder S., et al. SARS-CoV-2 Cell Entry Depends on ACE2 andTMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020;181(2):271-280.
3. Wrapp D., Wang N., Corbett KS., et al. Cryo-EM structure of the 2019-nCoV spike in the prefusionconformation. Science, 2020;367(6483):1260-1263.
4. Yin HS., Wen X., Paterson RG., Lamb RA., Jardetzky TS. Structure of the para influenza virus 5 Fprotein in its metastable, prefusion conformation. Nature, 2006;439(7072):38-44.
5. Amanat, F., Stadlbauer, D., Strohmeier, S., et al. A serological assay to detect SARS-CoV-2seroconversion in humans. Nat Med., 2020;26:1033-1036.
6. Stadlbauer, D., Amanat, F., Chromikova, V., et al. SARS?CoV?2 sero conversion in humans: A detailed protocol for a serological assay, antigen production, and test setup. Current Protocols in Microbiology, 2020;57, e100.
7. Korber, B., W. Fischer, Gnanakaran, S., et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell, 2020;182:1-16.
NCBI and Uniprot Product Information
UniProt Accession #
Molecular Weight
137 kDa
Estimated MW by SDS-PAGE: ~190kDa
Estimated MW by SDS-PAGE: ~190kDa
Similar Products
Product Notes
The COVID-19 (Catalog #AAA184019) is a Recombinant Protein produced from HEK293 Cells and is intended for research purposes only. The product is available for immediate purchase. The immunogen sequence is 16-1213aa. AAA Biotech's COVID 19 Spike protein (D614G variant) Coronavirus can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB), Immunoassay (IA), Functional Studies. Researchers should empirically determine the suitability of the COVID-19 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. The amino acid sequence is listed below: VNLTTRTQLP PAYTNSFTRG VYYPDKVFRS SVLHSTQDLF LPFFSNVTWF HAIHVSGTNG TKRFDNPVLP FNDGVYFAST EKSNIIRGWI FGTTLDSKTQ SLLIVNNATN VVIKVCEFQF CNDPFLGVYY HKNNKSWMES EFRVYSSANN CTFEYVSQPF LMDLEGKQGN FKNLREFVFK NIDGYFKIYS KHTPINLVRD LPQGFSALEP LVDLPIGINI TRFQTLLALH RSYLTPGDSS SGWTAGAAAY YVGYLQPRTF LLKYNENGTI TDAVDCALDP LSETKCTLKS FTVEKGIYQT SNFRVQPTES IVRFPNITNL CPFGEVFNAT RFASVYAWNR KRISNCVADY SVLYNSASFS TFKCYGVSPT KLNDLCFTNV YADSFVIRGD EVRQIAPGQT GKIADYNYKL PDDFTGCVIA WNSNNLDSKV GGNYNYLYRL FRKSNLKPFE RDISTEIYQA GSTPCNGVEG FNCYFPLQSY GFQPTNGVGY QPYRVVVLSF ELLHAPATVC GPKKSTNLVK NKCVNFNFNG LTGTGVLTES NKKFLPFQQF GRDIADTTDA VRDPQTLEIL DITPCSFGGV SVITPGTNTS NQVAVLYQGV NCTEVPVAIH ADQLTPTWRV YSTGSNVFQT RAGCLIGAEH VNNSYECDIP IGAGICASYQ TQTNSPGGAS VASQSIIAYT MSLGAENSVA YSNNSIAIPT NFTISVTTEI LPVSMTKTSV DCTMYICGDS TECSNLLLQY GSFCTQLNRA LTGIAVEQDK NTQEVFAQVK QIYKTPPIKD FGGFNFSQIL PDPSKPSKRS FIEDLLFNKV TLADAGFIKQ YGDCLGDIAA RDLICAQKFN GLTVLPPLLT DEMIAQYTSA LLAGTITSGW TFGAGAALQI PFAMQMAYRF NGIGVTQNVL YENQKLIANQ FNSAIGKIQD SLSSTASALG KLQDVVNQNA QALNTLVKQL SSNFGAISSV LNDILSRLDP PEAEVQIDRL ITGRLQSLQT YVTQQLIRAA EIRASANLAA TKMSECVLGQ SKRVDFCGKG YHLMSFPQSA PHGVVFLHVT YVPAQEKNFT TAPAICHDGK AHFPREGVFV SNGTHWFVTQ RNFYEPQIIT TDNTFVSGNC DVVIGIVNNT VYDPLQPELD SFKEELDKYF KNHTSPDVDL GDISGINASV VNIQKEIDRL NEVAKNLNES LIDLQELGKY EQYIKWPSGG SGYIPEAPRD GQAYVRKDGE WVLLSTFLGS HHHHHHHH. It is sometimes possible for the material contained within the vial of "COVID 19 Spike protein (D614G variant) Coronavirus, Recombinant Protein" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
